食管癌新辅助治疗研究现状与进展  

Research status and progress on neoadjuvant therapy for esophageal cancer

作　　者：朱军格 李建彬 张英杰 Zhu Junge;Li Jianbin;Zhang Yingjie(Department of Graduate,Shandong First Medical University and Shandong Academy of Medical Sciences,Ji’nan 250117,China;Department of Chest Radiation OncologyⅠ,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Ji’nan 250117,China)

机构地区：[1]山东第一医科大学(山东省医学科学院)研究生部,济南250117 [2]山东省肿瘤防治研究院(山东省肿瘤医院)胸部放疗一病区,山东第一医科大学(山东省医学科学院),济南250117

出　　处：《中华放射肿瘤学杂志》2022年第4期389-394,共6页Chinese Journal of Radiation Oncology

基　　金：国家自然科学基金面上项目(81773287);泰山学者(ts20190982)。

摘　　要：中国是食管癌高发的国家。近年来随着研究的深入,相较于单纯手术以及辅助治疗,新辅助治疗在局部晚期可切除食管癌中的价值得到临床医师的广泛认可。但不同新辅助治疗方案的选择得到的生存结果可能大相径庭,这其中有诸多问题尚无统一结论。本文结合相关文献综述了新辅助放化疗的放疗靶区、放疗剂量、化疗方案及其与手术时间间隔,以及靶向治疗和免疫治疗作食管癌新辅助治疗方法的研究现状及进展。China is a country with high incidence of esophageal cancer.In recent years,with the deepening research,the value of neoadjuvant therapy in locally advanced resectable esophageal cancer has been widely approved by clinicians,compared with surgery alone or adjuvant therapy.However,the survival results of different neoadjuvant therapy options may be quite different,and many problems remain unresolved.In this article,a systemic literature review was carried out to summarize the radiotherapy target,radiotherapy dose,chemotherapy regimen of neoadjuvant chemoradiotherapy and time to surgery,as well as review the research status and progress on targeted therapy and immunotherapy as neoadjuvant therapy for esophageal cancer.

关 键 词：食管肿瘤/新辅助化学疗法 食管肿瘤/新辅助放化疗法 食管肿瘤/靶向疗法 食管肿瘤/免疫疗法 

分 类 号：R735.1[医药卫生—肿瘤]